Request Trial
shutterstock_1137688736_shidlovski
Shidlovski / Shutterstock.com
8 February 2021EuropeJackie Mulryne

Second medical use: a regulatory perspective

As compound patents and regulatory data protection for medicinal products expire, pharmaceutical companies increasingly look to develop new uses for their products. This strategy usually involves filing second medical use patents to protect the invention and research investment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Emotional Perception exclusive: ‘We are now very much open for business’
16 February 2026   Following the UK Supreme Court’s recent landmark judgment, which ushers in a sea-change to patent law, the team behind a groundbreaking AI-related invention sit down with Sarah Speight to explain how they got here, and why the ruling changes everything.
Europe
UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents
12 February 2026   The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.
Europe
Reaction: Emotional Perception decision is ‘good for UK PLC’
12 February 2026   UK and European patent attorneys share their initial views after the UK Supreme Court delivered its landmark judgment, which “brings some much‑needed clarity and consistency” to the patentability of AI-related innovations—including those in the medtech industry.


Editor's picks

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026

Editor's picks

Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026

More features

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
Wiggin’s new litigation partner deepens ‘technically complex’ offer
Could everyday hospital equipment be the next defence against counterfeit medicines?
Mintz gains ex-Winston & Strawn partner and ITC expert
Hogan Lovells makes senior public and administrative hire in Italy
Danaher moves to acquire Masimo in $9.9bn deal
Generic rival blocked as AZ defends diabetes stronghold